Guía de Medicamentos

109 artículos

Todos los artículos
Guía de Medicamentos

Injection Tracker App for GLP-1: Features to Look For

Choosing an injection tracker app for GLP-1? Here are the must-have features — site-rotation body map, weekly reminders, dose log, missed-dose logic — and why it beats paper.

5 min
Guía de Medicamentos

Oral Wegovy Side Effects: Nausea & Warnings (2026)

Oral Wegovy's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild-to-moderate and worst during dose increases. Because oral Wegovy is the same molecule as injectable Wegovy (semaglutide), it shares the *same* side-effect profile and the *same* serious warnings, including pancreatitis, gallbladder disease, and a boxed thyroid warning.

10 min
Guía de Medicamentos

Orforglipron Side Effects: Nausea, Warnings (2026)

Orforglipron's most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — which are dose-dependent, tend to be worst around each dose increase, and usually settle as the body adapts. Rare but serious risks include a boxed warning for thyroid C-cell tumors plus pancreatitis and gallbladder disease, which need urgent medical care.

8 min
Guía de Medicamentos

Retatrutide Side Effects: Trial Data & Warnings 2026

In clinical trials, retatrutide's most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — mostly mild-to-moderate and worst during dose escalation. Its triple-agonist design also produces two distinctive signals: abnormal skin sensations (dysesthesia) and a modest heart-rate increase. Retatrutide is investigational and available only through clinical trials — it cannot be prescribed.

7 min
Guía de Medicamentos

Semaglutide vs Tirzepatide: Which Is Right for You? (2026)

Tirzepatide (Mounjaro, Zepbound) acts on two hormones (GIP + GLP-1) and produced greater average weight loss in trials (~21%) than semaglutide (Ozempic, Wegovy, ~15%). But semaglutide has the longer track record and strong cardiovascular data. The "better" one depends on your goals, tolerance, cost, and prescriber.

4 min
Guía de Medicamentos

GLP-1 Side Effects: Ozempic, Wegovy & Tirzepatide Guide (2026)

The most common GLP-1 side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — and they are usually mild, most likely when starting or increasing the dose, and tend to ease within a few weeks. Rare but serious risks include pancreatitis, gallbladder problems, and severe delayed stomach emptying, which need urgent medical attention.

8 min
Guía de Medicamentos

How Much Does Wegovy & Ozempic Cost in 2026? Full Price Breakdown

Without insurance, Ozempic and Wegovy have list prices of roughly $970–$1,350 per month. But almost nobody pays that. Through the manufacturer's cash-pay pharmacy (NovoCare), self-pay prices in 2026 are about $349–$499/month for the injection and $149–$299/month for the newer oral pill — and with commercial insurance plus a savings card, eligible patients can pay as little as $0–$25 a month.

7 min
Guía de Medicamentos

Mounjaro Side Effects: Nausea, Sulfur Burps & Timeline (2026)

Mounjaro's most common side effects are gastrointestinal — nausea, diarrhea, decreased appetite, vomiting, and constipation — usually mild and worst during dose increases. Many users also report sulfur ("egg") burps. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.

9 min
Guía de Medicamentos

Ozempic Side Effects: Nausea, Timeline & Warnings (2026)

Ozempic's most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — usually mild and worst during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent care.

9 min
Guía de Medicamentos

Semaglutide Side Effects: Ozempic, Wegovy & Rybelsus (2026)

Semaglutide's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Frequency depends on the product and dose: highest with Wegovy 2.4 mg (weight loss), lower with Ozempic and oral Rybelsus (diabetes). Rare serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.

10 min
Guía de Medicamentos

Tirzepatide Side Effects: Mounjaro & Zepbound (2026)

The most common tirzepatide side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent medical care.

9 min
Guía de Medicamentos

Wegovy Side Effects: Nausea, Hair Loss & Timeline (2026)

Wegovy's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Because Wegovy titrates to a higher 2.4 mg dose, these are reported more often than with Ozempic. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.

10 min
Guía de Medicamentos

Zepbound Side Effects: Nausea, Hair Loss & Timeline (2026)

Zepbound's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Injection-site reactions and hair loss are also labeled. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent care.

11 min
Guía de Medicamentos

GLP-1 Solo No Es Suficiente — El Modelo "Fármaco + Terapia Conductual" Recomendado por la OMS/ADA, y las Etapas M0/M1/M2 de HAVIT

Los agonistas del receptor GLP-1 (Wegovy, Mounjaro, Zepbound) producen una pérdida de peso promedio del 15–22% (STEP 1, SURMOUNT-1). Pero STEP 4 reportó una recuperación de +11.6%p un año después de la discontinuación — aproximadamente el 78% del peso perdido regresó. La OMS (2022) y los ADA Standards (2024) recomiendan explícitamente la terapia conductual junto con la farmacoterapia, y STEP 3 (JAMA 2021) mostró que la Terapia Conductual Intensiva en combinación logró casi 3× la pérdida de peso de la combinación con atención estándar (−16% vs −5.7%). HAVIT estructura esto en 3 etapas — pre-medicación (M0), adaptación (M1), mantenimiento/discontinuación (M2) — integrando fármacos, preservación muscular y aprendizaje conductual. HAVIT no prescribe GLP-1; la prescripción, dosificación y discontinuación permanecen en el dominio del médico.

14 min
Guía de Medicamentos

¿Puedo beber alcohol tomando semaglutida? Guía basada en evidencia 2026

El consumo ligero a moderado de alcohol (1-2 copas ocasionalmente) parece seguro para la mayoría de personas con semaglutida, pero los GLP-1 ralentizan el vaciado gástrico y pueden intensificar los efectos—conoce tus límites y vigila la hipoglucemia.

12 min

¿Listo para perder peso de forma más inteligente?

Todo lo que necesitas para bajar de peso, preservar músculo y crear hábitos saludables, en una sola app con IA.

Download on the App StoreGet it on Google Play

Descarga gratuita. Puede incluir compras dentro de la app.